vs
MYRIAD GENETICS INC（MYGN）与NEOGEN CORP（NEOG）财务数据对比。点击上方公司名可切换其他公司
NEOGEN CORP的季度营收约是MYRIAD GENETICS INC的1.1倍（$224.7M vs $209.8M）。MYRIAD GENETICS INC同比增速更快（-0.4% vs -2.8%）。过去两年MYRIAD GENETICS INC的营收复合增速更高（1.9% vs -0.9%）
麦利亚德基因公司是总部位于美国犹他州盐湖城的美国基因检测与精准医疗企业。公司拥有多项自主专利技术，帮助医生与患者了解人类疾病的遗传基础，以及基因在疾病发生、发展和治疗中发挥的作用，相关成果可用于开发评估患病风险、指导疾病诊疗的新产品。
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
MYGN vs NEOG — 直观对比
营收规模更大
NEOG
是对方的1.1倍
$209.8M
营收增速更快
MYGN
高出2.5%
-2.8%
两年增速更快
MYGN
近两年复合增速
-0.9%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $209.8M | $224.7M |
| 净利润 | — | $-15.9M |
| 毛利率 | 70.0% | 47.5% |
| 营业利润率 | -2.7% | -2.4% |
| 净利率 | — | -7.1% |
| 营收同比 | -0.4% | -2.8% |
| 净利润同比 | — | 96.5% |
| 每股收益（稀释后） | $-0.09 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MYGNNEOG
| Q4 25 | $209.8M | $224.7M | ||
| Q3 25 | $205.7M | $209.2M | ||
| Q2 25 | $213.1M | $225.4M | ||
| Q1 25 | $195.9M | $221.0M | ||
| Q4 24 | $210.6M | $231.3M | ||
| Q3 24 | $213.3M | $217.0M | ||
| Q2 24 | $211.5M | $236.8M | ||
| Q1 24 | $202.2M | $228.8M |
净利润MYGNNEOG
| Q4 25 | — | $-15.9M | ||
| Q3 25 | $-27.4M | $36.3M | ||
| Q2 25 | $-330.5M | $-612.3M | ||
| Q1 25 | $-100.0K | $-10.9M | ||
| Q4 24 | — | $-456.3M | ||
| Q3 24 | $-22.1M | $-12.6M | ||
| Q2 24 | $-36.7M | $-5.4M | ||
| Q1 24 | $-26.0M | $-2.0M |
毛利率MYGNNEOG
| Q4 25 | 70.0% | 47.5% | ||
| Q3 25 | 69.9% | 45.4% | ||
| Q2 25 | 71.2% | 41.2% | ||
| Q1 25 | 68.5% | 49.9% | ||
| Q4 24 | 71.7% | 49.0% | ||
| Q3 24 | 70.2% | 48.4% | ||
| Q2 24 | 69.6% | 47.9% | ||
| Q1 24 | 68.1% | 51.1% |
营业利润率MYGNNEOG
| Q4 25 | -2.7% | -2.4% | ||
| Q3 25 | -11.3% | -7.7% | ||
| Q2 25 | -154.5% | -271.1% | ||
| Q1 25 | -14.8% | 2.4% | ||
| Q4 24 | -18.6% | -197.8% | ||
| Q3 24 | -9.4% | 1.0% | ||
| Q2 24 | -17.3% | 5.5% | ||
| Q1 24 | -13.8% | 5.3% |
净利率MYGNNEOG
| Q4 25 | — | -7.1% | ||
| Q3 25 | -13.3% | 17.4% | ||
| Q2 25 | -155.1% | -271.6% | ||
| Q1 25 | -0.1% | -4.9% | ||
| Q4 24 | — | -197.3% | ||
| Q3 24 | -10.4% | -5.8% | ||
| Q2 24 | -17.4% | -2.3% | ||
| Q1 24 | -12.9% | -0.9% |
每股收益（稀释后）MYGNNEOG
| Q4 25 | $-0.09 | $-0.07 | ||
| Q3 25 | $-0.29 | $0.17 | ||
| Q2 25 | $-3.57 | $-2.82 | ||
| Q1 25 | $0.00 | $-0.05 | ||
| Q4 24 | $-0.47 | $-2.10 | ||
| Q3 24 | $-0.24 | $-0.06 | ||
| Q2 24 | $-0.41 | $-0.02 | ||
| Q1 24 | $-0.29 | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $149.6M | $145.3M |
| 总债务越低越好 | $119.9M | — |
| 股东权益账面价值 | $368.0M | $2.1B |
| 总资产 | $706.6M | $3.4B |
| 负债/权益比越低杠杆越低 | 0.33× | — |
8季度趋势，按日历期对齐
现金及短期投资MYGNNEOG
| Q4 25 | $149.6M | $145.3M | ||
| Q3 25 | $145.4M | $138.9M | ||
| Q2 25 | $74.4M | $129.0M | ||
| Q1 25 | $91.8M | $127.7M | ||
| Q4 24 | $102.4M | $140.2M | ||
| Q3 24 | $99.9M | $120.5M | ||
| Q2 24 | $97.3M | $170.9M | ||
| Q1 24 | $104.3M | $168.4M |
总债务MYGNNEOG
| Q4 25 | $119.9M | — | ||
| Q3 25 | $119.5M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MYGNNEOG
| Q4 25 | $368.0M | $2.1B | ||
| Q3 25 | $372.8M | $2.1B | ||
| Q2 25 | $388.1M | $2.1B | ||
| Q1 25 | $704.9M | $2.7B | ||
| Q4 24 | $701.1M | $2.7B | ||
| Q3 24 | $731.7M | $3.1B | ||
| Q2 24 | $740.5M | $3.1B | ||
| Q1 24 | $760.0M | $3.1B |
总资产MYGNNEOG
| Q4 25 | $706.6M | $3.4B | ||
| Q3 25 | $728.1M | $3.4B | ||
| Q2 25 | $677.3M | $3.4B | ||
| Q1 25 | $1.0B | $4.0B | ||
| Q4 24 | $1.0B | $4.1B | ||
| Q3 24 | $1.1B | $4.5B | ||
| Q2 24 | $1.1B | $4.5B | ||
| Q1 24 | $1.1B | $4.6B |
负债/权益比MYGNNEOG
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $10.6M | $19.4M |
| 自由现金流经营现金流 - 资本支出 | — | $7.8M |
| 自由现金流率自由现金流/营收 | — | 3.5% |
| 资本支出强度资本支出/营收 | — | 5.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-18.5M |
8季度趋势，按日历期对齐
经营现金流MYGNNEOG
| Q4 25 | $10.6M | $19.4M | ||
| Q3 25 | $21.1M | $10.9M | ||
| Q2 25 | $-13.6M | $16.4M | ||
| Q1 25 | $-16.3M | $19.5M | ||
| Q4 24 | $6.6M | $40.3M | ||
| Q3 24 | $700.0K | $-17.9M | ||
| Q2 24 | $2.6M | $26.7M | ||
| Q1 24 | $-18.6M | $-30.2M |
自由现金流MYGNNEOG
| Q4 25 | — | $7.8M | ||
| Q3 25 | — | $-13.1M | ||
| Q2 25 | — | $349.0K | ||
| Q1 25 | — | $-13.4M | ||
| Q4 24 | — | $23.1M | ||
| Q3 24 | — | $-56.3M | ||
| Q2 24 | — | $2.5M | ||
| Q1 24 | — | $-62.3M |
自由现金流率MYGNNEOG
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | -6.3% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | — | 10.0% | ||
| Q3 24 | — | -26.0% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | -27.2% |
资本支出强度MYGNNEOG
| Q4 25 | — | 5.2% | ||
| Q3 25 | — | 11.5% | ||
| Q2 25 | — | 7.1% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | — | 17.7% | ||
| Q2 24 | — | 10.2% | ||
| Q1 24 | — | 14.0% |
现金转化率MYGNNEOG
| Q4 25 | — | — | ||
| Q3 25 | — | 0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MYGN
暂无分部数据
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
